Evidence map›Paper›PMID 41921980›Full record

ArticleJournal of natural products2026

Native Metabolomics Unveils Suomilide Analogs with Potent Trypsin Inhibitory Activity.

Amira Naimi, Christoph Ulbricht, Tung Lam Trinh, Stefan Kehraus, Teresa Marina Dreckmann, Uwe Linne, Kornelia Hardes, Raphael Reher, Martin Baunach

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of natural products, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amira NaimiInstitute of Pharmaceutical Biology and Biotechnology, Marburg University, Robert-Koch-Str. 4, 35037 Marburg, Germany.ORCID 0009-0009-2738-1687
Christoph UlbrichtInstitute of Pharmaceutical Biology, University of Bonn, Nussallee 6, 53115 Bonn, Germany.ORCID 0009-0000-1182-6172
Tung Lam TrinhInstitute of Pharmaceutical Biology, University of Bonn, Nussallee 6, 53115 Bonn, Germany.
Stefan KehrausInstitute of Pharmaceutical Biology, University of Bonn, Nussallee 6, 53115 Bonn, Germany.
Teresa Marina DreckmannInstitute of Pharmaceutical Biology, University of Bonn, Nussallee 6, 53115 Bonn, Germany.
Uwe LinneDepartment of Chemistry, Philipps-Universität Marburg, Hans-Meerwein-Straße 4, 35043 Marburg, Germany.
Kornelia HardesFraunhofer Institute for Molecular Biology and Applied Ecology - Branch for Bioresources, Ohlebergsweg 12, 35392 Gießen, Germany.
Raphael ReherInstitute of Pharmaceutical Biology and Biotechnology, Marburg University, Robert-Koch-Str. 4, 35037 Marburg, Germany.ORCID 0000-0002-5858-1173
Martin BaunachInstitute of Pharmaceutical Biology, University of Bonn, Nussallee 6, 53115 Bonn, Germany.ORCID 0000-0003-0822-1468

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyanobacteria are well-known for their ability to produce a diverse array of serine protease inhibitors and thus are a promising source of pharmaceutical lead structures. Here, native metabolomics was employed with trypsin to rapidly screen whole cyanobacterial metabolomes and uncover new potent inhibitors. In combination with subsequent correlative LC-HR-MS/MS-based analysis, this led to the fast discovery of the well-characterized natural product family of suomilides from

Indexed as

MetabolomicsNostocTrypsin InhibitorsMolecular StructureNuclear Magnetic Resonance, BiomolecularTrypsin Inhibitors

Identifiers

PMID41921980
PMCPMC13122637

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.